Cingulate Advances ADHD Treatment Toward 2026 FDA Decision with Key Milestones
Cingulate Inc. progresses toward potential 2026 commercial launch of its ADHD treatment CTx-1301 following FDA acceptance of its New Drug Application and positive pediatric trial results, addressing a large market with unmet needs.
